While demonstrated here for the first time in the context of HER2i therapy resistance, genetic DUSP6 inhibition has recently been shown to inhibit malignant phenotypes in other cancer types (Shojaee et al, 2015; Wu et al, 2018; Zandi et al, 2022). Here, DUSP6 is linked to cancer.